-Whereas ANH patients underwent additionally preoperative autologous deposit (PAD), control patients did not [6] . -There are statistically significant and clinically relevant differences between patients in the control group and in the ANH group [7] . -Based on their results some authors draw conclusions that are difficult to follow [8] . Mathematical modelling (MM) of ANH consistently demonstrates that net saving of rbc mass due to ANH is rather small [9] [10] [11] [12] [13] [14] [15] . With an initial hct of approximately 40% and with 3 units of blood collected (each 500 ml), the minimal hct level accepted has to be (≤)24%, in order to save approximately 140 ml of rbc [14, 15] . These data from MM are in very good agreement with findings from clinical studies [16] [17] [18] . The conclusions drawn from MM for ANH with respect to its effectiveness are confirmed by clinical trials: -'… the modest benefit of only 1 unit of blood with either ANH or PAD suggests that transfusion outcomes might be similar even if no blood conservation interventions were used' [18] . -'… if autologous blood procurement is requested for patients undergoing procedures unlikely to require transfusion, ANH is preferable to PAD in view of reduced costs associated with ANH' [19] . MM demonstrate ANH to be beneficial as a blood-saving measure if the (expected) blood loss is ≥2.0-2.5 l (i.e. approximately 50% of the patient's blood volume) [14, 15] and if a (very) low minimal hct value / 'transfusion trigger', in the range of ≤20%, is accepted [12, 14, 15, 21] . (… 'if the surgical blood loss fails to exceed a minimum value, hemodilution fails to offer any savings' [20, 21] ). When discussing the effectiveness of ANH as a 'blood saving measure', one has to differentiate very clearly between saving of rbc, the benefit of which by ANH is small, and reducing/avoiding the need for allogeneic blood, which can be tremendous under optimal and extreme conditions [12, 14, 15] . This distinction can best be done by MM of ANH. Substituting 'ml of blood loss' by 'ml of ANH blood' results in an identical maximally allowable blood loss (MABL) for ANH and for non-ANH. However, ANH patients reach a higher hct value than non-ANH patients. Replacing 'ml of rbc lost' by 'ml of ANH rbc', while maintaining minimal hct and normovolemia by additional infusion of a cell-free solution, results in a MABL clearly beyond the volume of ANH blood collected [11, 12, 14, 15] . (The lower the minimal hct level accepted, the smaller the rbc mass to be retransfused to maintain this level despite ongoing blood loss, and the higher MABL correspondingly).
Effectiveness of Acute Normovolemic Hemodilution to Reduce the Need for Allogeneic Blood
Statement of the Working Group 'Autologous Haemotherapy' DGTI Acute normovolamic hemodilution (ANH) is considered an effective measure to reduce the need for allogeneic blood. With respect to its mechanism it is understood very well: Due to preoperative ANH, red blood cell (rbc) mass lost during surgery is smaller than without ANH [1] . rbc mass collected by ANH is retransfused either during or after surgery according to the individual patient's need. This is thought to reduce/avoid allogeneic blood transfusions. Dilution-induced decline in oxygen content is believed to be compensated by a supranormal increase in relative oxygen transport capacity [2] . However, this assumption is not accepted unequivocally [3] . Studies describing a clear-cut decrease in allogeneic blood supply in patients with ANH warrant close and careful analysis: -Retrospective data from patients without ANH were compared with prospective data from patients with ANH [4, 5] . -'Transfusion trigger' in control patients and in ANH patients differ significantly; this difference is of clinical relevance [6] . In ANH patients, the corresponding hematocrit (hct) level is by approximately 13% lower (15% versus 28%) than in control patients [6] .
The restricted assessment by MM of ANH as a rbc/blood saving measure is supported by the data of 2 meta-analyses on this topic [22, 23] and by the Conference Report of the Royal College of Physicians of Edinburgh [24] stating that: -'Closer examination suggests that these reductions in blood exposure may be due to flawed study design. … studies with a transfusion protocol failed to show statistically significant reductions in either the likelihood of receiving an allogeneic transfusion or the allogeneic units transfused' [22] . -'… additional trials that tightly control patients sampling and study design are required' [23] . -'There is still no evidence that ANH is effective in reducing red cell transfusion' [24] . In conclusion we state: -Very often, effectiveness of ANH as rbc/blood saving measure is exaggerated far too much. -Effectiveness of ANH depends very decisively on the initial hct value, the number of ANH units collected preoperatively, the minimal hct level accepted, the extent of surgical blood loss, and the manner of retransfusing ANH blood and substituting blood loss / loss of rbc. -Therefore, ANH should only be administered under strictly defined conditions: initial hct ≥40%, minimal hct value accepted ≤24% or 21%, collection of (at least 3 to) 4 units of ANH-blood, 500 ml each (i.e. 20-30 ml per kg body weight), expected total blood loss of (at least) approximately 2.0-2.5 l (i.e. approximately 50% of the patient's estimated blood volume). -It is less the preoperative collection of rbc/blood by ANH than rather the extent of dilution anemia accepted ((very) low 'transfusion trigger' / minimal hct value) and its maintaining that enable ANH to compensate for an increase in surgical MABL without additional allogeneic blood transfusion. -By defining a critical and individually based indication for ANH, unnecessary and probably insufficient but also costrelevant acute autologous blood collection and its retransfusion can be avoided. Neither benefits are withheld from the patient nor will any harm be done to the patient. 
Indikation und Durchführung einer Genotypisierung thrombozytärer Antigene
Nach dem derzeitigen Kenntnisstand der Arbeitsgruppe bestehen nachfolgende Indikationen für die Durchführung einer Typisierung der humanen Plättchen-Antigene (HPA). Lediglich die Untersuchung der Systeme HPA-1 und HPA-5 wird empfohlen. Die Genotypisierung für HPA-2 und HPA-3 sowie anderer HPA-Systeme ist in der deutschsprachigen Bevölkerung im Routinefall entbehrlich, da Antikörper in diesen Antigen-Systemen extrem selten beobachtet werden. 
